leisure time -WSS

leisure time

author：leisure time 2025-09-27 09:45:33 - browse：2

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Ascension's ugly legal battle over care for poor patients in Texas

hotspot

WSS

Fatty liver disease was alleviated by Lilly’s ‘triple

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

The wait for US passports is creating travel purgatory and snarling summer plans

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Canadians with cystic fibrosis outlive Americans by a decade

explore

leisure time

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Canadians with cystic fibrosis outlive Americans by a decade

Alkermes shareholders re

A preacher's new calling: Diversifying neuroscience research

Medicare proposal to cover medical devices draws a mixed reaction

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Supreme Court strikes down use of affirmative action

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage coverage denials need scrutiny, senators say

knowledge

Boston Scientific acquires urology company Axonics for $3.7 billion

Gene therapy denied for Afghan refugee whose father aided U.S.

Medicare Advantage overpayments discussion gets experts fired up

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Medicare Advantage overpayments discussion gets experts fired up

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

explore

hotspot

leisure time

Wikipedia